In the HOVON68 CLL trial, patients 65 to 75 years of age had no survival benefit from the addition of low-dose alemtuzumab to fludarabine and cyclophosphamide (FC) in contrast to younger patients. The reasons are explored in this 5-year trial update using both survival analysis and competing risk analysis on non-CLL-related mortality. Elderly FCA patients died more frequently from causes not related to CLL, and more often related to comorbidity (mostly cardiovascular) than to infection. In a Cox multivariate analysis, del(17p), performance status >0, and comorbidity were associated with a higher non-CLL-related mortality in the elderly independent of the treatment modality. Thus, while the ‘fit’ elderly with no comorbidity or performance status of 0 might potentially benefit from chemo-immunotherapy with FC, caution is warranted, when considering alemtuzumab treatment in elderly patients with cardiovascular comorbidity.

alemtuzumab, chemo-immunotherapy, CLL, comorbidity, elderly, performance status,
Leukemia and Lymphoma

Vojdeman, F.J, van 't Veer, M.B, Tjønnfjord, G, Itälä Remes, M, Kimby, E, Polliack, A, … Geisler, C.H. (Christian Hartmann). (2017). The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 58(3), 594–600. doi:10.1080/10428194.2016.1213831